A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder
Status:
Completed
Trial end date:
2019-02-22
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety and tolerability of rapastinel 450 milligrams
(mg) intravenous (IV) once weekly or once every 2 weeks versus placebo as an adjunctive
treatment to ongoing anti-depressive therapy (ADT) in the prevention of relapse in
participants with Major Depressive Disorder (MDD).
Phase:
Phase 3
Details
Lead Sponsor:
Allergan Naurex, Inc, an affiliate of Allergan plc